Annovis Bio (ANVS) Stock Forecast & Price Target

$6.75 -0.09 (-1.32%)

(As of 01:55 PM ET)

Annovis Bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
1

Buy
6

Based on 7 Wall Street analysts who have issued ratings for Annovis Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 1 has given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for ANVS.

Consensus Price Target

$32.17
376.54% Upside

According to the 7 analysts' twelve-month price targets for Annovis Bio, the average price target is $32.17. The highest price target for ANVS is $67.00, while the lowest price target for ANVS is $9.00. The average price target represents a forecasted upside of 376.54% from the current price of $6.75.

Get the Latest News and Ratings for ANVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Annovis Bio and its competitors.

ANVS Analyst Ratings Over Time

Type	Current Forecast 11/19/23 to 11/18/24	1 Month Ago 10/20/23 to 10/19/24	3 Months Ago 8/21/23 to 8/20/24	1 Year Ago 11/19/22 to 11/19/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	2 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$32.17	$33.60	$33.60	$32.50
Forecasted Upside	376.54% Upside	264.82% Upside	277.10% Upside	435.42% Upside
Consensus Rating	Buy	Buy	Buy	Buy

I was wrong. Dead wrong. (Ad)

One small investment into these three companies at IPO and you’ve outperformed almost any other investment you could make. Unfortunately, you can’t go back in time and invest in what became the three most dominant companies in the tech world.

Click here to watch.

ANVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ANVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Annovis Bio Stock vs. The Competition

Type	Annovis Bio	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	362.16% Upside	28,123.88% Upside	9.53% Upside
News Sentiment Rating	Neutral News See Recent ANVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00	+267.65%
10/25/2024	Maxim Group 4 of 5 stars	J. Mccarthy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$25.00	+175.63%
8/13/2024	EF Hutton Acquisition Co. I 1 of 5 stars	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2024	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$67.00 ➝ $67.00	+842.33%
4/30/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$36.00 ➝ $26.00	+256.65%
2/28/2024	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Bussian Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$9.00	-7.98%
Get the Latest News and Ratings for ANVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:18 PM ET.

ANVS Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Annovis Bio is $32.17, with a high forecast of $67.00 and a low forecast of $9.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There is currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ANVS shares.
: According to analysts, Annovis Bio's stock has a predicted upside of 376.54% based on their 12-month stock forecasts.
: Over the previous 90 days, Annovis Bio's stock had 1 upgrade by analysts.
: Annovis Bio has been rated by research analysts at HC Wainwright, and Maxim Group in the past 90 days.
: Analysts like Annovis Bio more than other "medical" companies. The consensus rating for Annovis Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ANVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Wall St Legend Issues No. 1 Melt-Up Stock Pick (Ad)

Investors poured a staggering $56 billion into U.S. stock funds in just one week — the second-largest inflow since 2008... Nearly 50% of investors now describe themselves as bullish — the highest sentiment level since 2022...

Click here to watch Whitney Tilson's full market briefing and claim your free stock pick today.

This page (NYSE:ANVS) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Stock Forecast & Price Target